Discovery of 1,3,4‐Oxadiazin‐5‐One Derivative CJ1‐34 as a Partial ATP Synthase Inhibitor for CNS Applications
Chemistry – A European Journal · 2025
DOI: 10.1002/chem.202404517 ↗Kurz gefasst
Fachartikel in der Zeitschrift Chemistry – A European Journal, 2025. Verfasst von Caitlin V M L Jie und 7 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, CH-8093, Zurich, Switzerland. Hauptthemen laut MEDLINE: Mitochondrial Proton-Translocating ATPases, Enzyme Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung, Novartis Institutes for BioMedical Research.
Abstract (Originalsprache)
ATP synthase dysregulation has been implicated in many diseases, including cancer and neurodegenerative diseases. Whilst ATP synthase‐targeting compounds have been reported, most are large or polar compounds and lack appropriate properties for a CNS drug. We designed, synthesised, and evaluated a novel series of ATP synthase targeting compounds, resulting in a 1,3,4‐oxadiazin‐5‐one scaffold with improved physiochemical properties. In vitro evaluation of our library led to the discovery of CJ1‐34 as a partial ATP synthase inhibitor with a determined IC 50 of 394 nM in isolated bovine mitochondria. Molecular docking experiments demonstrated that calculated docking scores aligned with the observed in vitro pharmacology and supports the F 1 region of the ATP synthase as the potential binding site. Overall, this provides the foundation to further investigate CJ1‐34 as a potential CNS drug for diseases where mitochondria are implicated, including Alzheimer's and Parkinson's disease.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Institute of Pharmaceutical Sciences, Department of Chemistry and Applied Biosciences, ETH Zürich, CH-8093, Zurich, Switzerland.
ORCID-Profile: Caitlin V M L Jie, Aro Delparente, Lisa Reichert, Kenneth Atz, Roger Schibli, Linjing Mu
Förderung
- Schweizerischer Nationalfonds zur Förderung der Wissenschaftlichen Forschung
- Novartis Institutes for BioMedical Research
Zitieren
APA
Jie, C. V. M. L., Delparente, A., Reichert, L., Albrecht, M., Atz, K., Schneider, G., Schibli, R., & Mu, L. (2025). Discovery of 1,3,4‐Oxadiazin‐5‐One Derivative CJ1‐34 as a Partial ATP Synthase Inhibitor for CNS Applications. Chemistry – A European Journal. https://doi.org/10.1002/chem.202404517
Vancouver
Jie CVML, Delparente A, Reichert L, Albrecht M, Atz K, Schneider G, et al. Discovery of 1,3,4‐Oxadiazin‐5‐One Derivative CJ1‐34 as a Partial ATP Synthase Inhibitor for CNS Applications. Chemistry – A European Journal. 2025. doi:10.1002/chem.202404517
BibTeX
@article{Jie2025,
author = {Jie, Caitlin V M L and Delparente, Aro and Reichert, Lisa and Albrecht, Manuela and Atz, Kenneth and Schneider, Gisbert and Schibli, Roger and Mu, Linjing},
title = {Discovery of 1,3,4‐Oxadiazin‐5‐One Derivative CJ1‐34 as a Partial ATP Synthase Inhibitor for CNS Applications},
journal = {Chemistry – A European Journal},
year = {2025},
doi = {10.1002/chem.202404517}
}
EUVIMED